Comparative Validation of "Blinq" and "2WIN" Vision Screeners

Sponsor
Alaska Blind Child Discovery (Other)
Overall Status
Completed
CT.gov ID
NCT04195711
Collaborator
(none)
100
1
8
380.5

Study Details

Study Description

Brief Summary

After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending.

Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: objective pediatric vision screen, "blinq,"

Detailed Description

As a part of a new or follow-up comprehensive eye examinations, patients were screened with two novel objective devices according to AAPOS Uniform guidelines. Following the refractive, alignment and sensory testing, cycloplegic refraction was performed 30 or more minutes after cyclopentolate 1% drops. In cooperative patients, sensory tests including Worth 4-dot, Stereo Fly and "PDI Check" were performed to characterize binocularity. For younger patients, binocular function was estimated by Bruckner Test, 4- base out prism cover and the CR corneal reflex component of "2WIN" photoscreener ("Adaptica," Padova Italy).

Each patient was screened with a recently commercially released blinq screener according to manufacturer's recommendations. If an initial interpretation of "pass" or "refer" was not achieved, then repeat efforts with "timed out" or "inconclusive" were accomplished and results evaluated as if a "refer." An example of blinq birefringent screening is shown in [video].

Patients were screened with the binocular infrared autorefractor "2WIN" according to manufacturer guidelines. Refractive referral criteria were not age-stratified.

The "Rebion blinq" is a unique screening method and therefore we sought to provide appropriate validation. In addition to non-age stratified AAPOS 2003 Uniform guidelines, we collected all cases characterized by constant or persistent strabismus whether large- or small angle employing cover test, 4 base out test, Bruckner Test and "2WIN CR" function. We did not employ any method of retinal videographic analysis of fixation instability.

De-identified patient data recorded for sharing on study website.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparative Validation of the Birefringent Amblyopia Screener With Isolated Small-angle Strabismus
Actual Study Start Date :
Nov 18, 2019
Actual Primary Completion Date :
Nov 26, 2019
Actual Study Completion Date :
Nov 26, 2019

Arms and Interventions

Arm Intervention/Treatment
blinq screened

Patients screened by new birefringent screener

Diagnostic Test: objective pediatric vision screen, "blinq,"
hand-held birefringent screener for simultaneous foveation
Other Names:
  • photoscreen, birefringent screen
  • Outcome Measures

    Primary Outcome Measures

    1. 2003 AAPOS Uniform Amblyopia Risk Factor (ARF) Prevalence [1 week]

      presence of refractive risk factor (anisometropia >1.5 D, hyperopia>3.5 D, astigmatism ≥1.5 D, myopia 3 D or more) and/or strabismus constant >10 PD

    Secondary Outcome Measures

    1. Binocularity [1 week]

      Any defective Sensory (stereopsis > 200 sec arc, ocular Worth 4-Dot suppression distance and/or near) and/or objective ocular alignment (positive Bruckner Test, positive 4 prism base out test, or "2WIN" "CR" corneal reflex alignment > 10 PD)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 65 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    Children in Pediatric Ophthalmology Practice Adult strabismus patients

    -

    Exclusion Criteria:

    patients with enucleations patients with eviscerations patients with exenterations

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Alaska Children's EYE & Strabismus Anchorage Alaska United States 99508

    Sponsors and Collaborators

    • Alaska Blind Child Discovery

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Alaska Blind Child Discovery
    ClinicalTrials.gov Identifier:
    NCT04195711
    Other Study ID Numbers:
    • ABCD blinq 2WIN
    First Posted:
    Dec 12, 2019
    Last Update Posted:
    Oct 19, 2020
    Last Verified:
    Dec 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Alaska Blind Child Discovery
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 19, 2020